Atracurium besylate 10mg/mL; soln for IV inj. <1month: not recommended. Individualize. 1month to 2yrs (under halothane anesthesia): initially 0.3–0.4mg/kg. ≥2yrs: initially 0.4–0.5mg/kg IV bolus.

NEW DELHI: Drug major Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Atracurium Besylate injections in the American market. "The company has ...

Sagent Pharmaceuticals announced the launch of Atracurium Besylate Injection, the generic form of the neuromuscular blocker Tracrium, in 50 mg per 5mL latex-free vials. Atracurium Besylate Injection ...

Review the side-effects of Atracurium as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please read this leaflet carefully before you are given DBL Atracurium Besylate Injection (Atracurium), even if you have had this medicine before. This leaflet answers some common questions about DBL™ ...

Learn everything you need to know about Atracurium-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

The company voluntarily recalls product due to FDA observations of potential sterility problems. FDA announced on Feb. 23, 2015 that Sagent Pharmaceuticals has issued a voluntary recall of two lots of ...

Aurobindo Pharma Ltd has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Atracurium Besylate Injection, 10mg/mL, 5mL single-dose vials and 10mg/mL, ...